| 0 |
PRIMARY STABBING HEADACHE |
1 |
0.0141 |
| 1 |
ONYCHOMALACIA |
1 |
0.0080 |
| 2 |
APPLICATION SITE HYPOAESTHESIA |
1 |
0.0043 |
| 3 |
RIB DEFORMITY |
1 |
0.0039 |
| 4 |
EAR OPERATION |
1 |
0.0027 |
| 5 |
BODY DYSMORPHIC DISORDER |
1 |
0.0027 |
| 6 |
TEMPOROMANDIBULAR PAIN AND DYSFUNCTION SYNDROME |
1 |
0.0023 |
| 7 |
FUNGAL FOOT INFECTION |
1 |
0.0023 |
| 8 |
SHORT-BOWEL SYNDROME |
1 |
0.0015 |
| 9 |
INFUSION SITE INFLAMMATION |
1 |
0.0014 |
| 10 |
IMMUNISATION REACTION |
1 |
0.0014 |
| 11 |
PRODUCT CONTAINER SEAL ISSUE |
2 |
0.0011 |
| 12 |
PRODUCT OUTER PACKAGING ISSUE |
1 |
0.0011 |
| 13 |
INFUSION SITE DISCOMFORT |
1 |
0.0010 |
| 14 |
NAIL GROWTH ABNORMAL |
1 |
0.0009 |
| 15 |
CHEMICAL BURN |
1 |
0.0009 |
| 16 |
FAT TISSUE INCREASED |
1 |
0.0007 |
| 17 |
APPLICATION SITE DRYNESS |
2 |
0.0006 |
| 18 |
PANCREATIC CYST |
1 |
0.0005 |
| 19 |
INFUSION SITE BRUISING |
1 |
0.0005 |
| 20 |
PRODUCT PACKAGE ASSOCIATED INJURY |
1 |
0.0004 |
| 21 |
INGROWING NAIL |
1 |
0.0004 |
| 22 |
PRODUCT INEFFECTIVE FOR UNAPPROVED USE |
1 |
0.0004 |
| 23 |
ONYCHOCLASIS |
2 |
0.0003 |
| 24 |
SNORING |
1 |
0.0003 |
| 25 |
FUNGAL SKIN INFECTION |
1 |
0.0002 |
| 26 |
APPLICATION SITE EXFOLIATION |
1 |
0.0002 |
| 27 |
INCORRECT DRUG ADMINISTRATION RATE |
1 |
0.0002 |
| 28 |
PRODUCT CONTAINER ISSUE |
2 |
0.0002 |
| 29 |
ONYCHOMYCOSIS |
1 |
0.0002 |
| 30 |
VASCULAR DEVICE INFECTION |
1 |
0.0002 |
| 31 |
GASTROINTESTINAL SOUNDS ABNORMAL |
1 |
0.0002 |
| 32 |
APPLICATION SITE SWELLING |
1 |
0.0002 |
| 33 |
HYPERAMMONAEMIA |
1 |
0.0002 |
| 34 |
PRODUCT DELIVERY MECHANISM ISSUE |
1 |
0.0002 |
| 35 |
BACK INJURY |
2 |
0.0002 |
| 36 |
PRODUCT LEAKAGE |
1 |
0.0002 |
| 37 |
APPETITE DISORDER |
1 |
0.0002 |
| 38 |
PRODUCT DOSE OMISSION IN ERROR |
4 |
0.0001 |
| 39 |
FAECES SOFT |
1 |
0.0001 |
| 40 |
LIQUID PRODUCT PHYSICAL ISSUE |
1 |
0.0001 |
| 41 |
PYELONEPHRITIS |
1 |
0.0001 |
| 42 |
NAIL DISORDER |
1 |
0.0001 |
| 43 |
INJECTION SITE DISCOMFORT |
1 |
0.0001 |
| 44 |
THYROID CANCER |
1 |
0.0001 |
| 45 |
APPLICATION SITE IRRITATION |
1 |
0.0001 |
| 46 |
DERMATITIS ALLERGIC |
1 |
0.0001 |
| 47 |
INJECTION SITE IRRITATION |
1 |
0.0001 |
| 48 |
TACHYPNOEA |
1 |
0.0001 |
| 49 |
SKIN IRRITATION |
3 |
0.0001 |
| 50 |
THYROID DISORDER |
1 |
0.0001 |
| 51 |
THERAPY PARTIAL RESPONDER |
1 |
0.0001 |
| 52 |
PRODUCT USE COMPLAINT |
1 |
0.0001 |
| 53 |
SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION |
1 |
0.0001 |
| 54 |
GASTROENTERITIS VIRAL |
1 |
0.0001 |
| 55 |
PRODUCT ADMINISTERED AT INAPPROPRIATE SITE |
1 |
0.0001 |
| 56 |
INJECTION SITE WARMTH |
1 |
0.0000 |
| 57 |
MOUTH ULCERATION |
1 |
0.0000 |
| 58 |
JOINT INJURY |
1 |
0.0000 |
| 59 |
GLYCOSYLATED HAEMOGLOBIN INCREASED |
1 |
0.0000 |
| 60 |
EXPOSURE VIA SKIN CONTACT |
1 |
0.0000 |
| 61 |
DEAFNESS |
1 |
0.0000 |
| 62 |
APPLICATION SITE ERYTHEMA |
1 |
0.0000 |
| 63 |
DERMATITIS ATOPIC |
2 |
0.0000 |
| 64 |
PAIN OF SKIN |
1 |
0.0000 |
| 65 |
LIMB INJURY |
1 |
0.0000 |
| 66 |
DEVICE DELIVERY SYSTEM ISSUE |
1 |
0.0000 |
| 67 |
INTENTIONAL DOSE OMISSION |
1 |
0.0000 |
| 68 |
BLOOD POTASSIUM DECREASED |
1 |
0.0000 |
| 69 |
LACRIMATION INCREASED |
1 |
0.0000 |
| 70 |
CYSTITIS |
1 |
0.0000 |
| 71 |
CHOLELITHIASIS |
1 |
0.0000 |
| 72 |
EYE PRURITUS |
1 |
0.0000 |
| 73 |
TRANSIENT ISCHAEMIC ATTACK |
1 |
0.0000 |
| 74 |
BLINDNESS |
1 |
0.0000 |
| 75 |
SKIN EXFOLIATION |
2 |
0.0000 |
| 76 |
THERAPY CESSATION |
1 |
0.0000 |
| 77 |
PERIPHERAL SWELLING |
3 |
0.0000 |
| 78 |
ILLNESS |
2 |
0.0000 |
| 79 |
ACCIDENTAL EXPOSURE TO PRODUCT |
2 |
0.0000 |
| 80 |
ECZEMA |
1 |
0.0000 |
| 81 |
INFLUENZA |
2 |
0.0000 |
| 82 |
BLISTER |
1 |
0.0000 |
| 83 |
ASTHMA |
2 |
0.0000 |
| 84 |
FLATULENCE |
1 |
0.0000 |
| 85 |
DYSPHONIA |
1 |
0.0000 |
| 86 |
SURGERY |
1 |
0.0000 |
| 87 |
THERAPEUTIC RESPONSE DECREASED |
1 |
0.0000 |
| 88 |
ALANINE AMINOTRANSFERASE INCREASED |
1 |
0.0000 |
| 89 |
INFUSION RELATED REACTION |
1 |
0.0000 |
| 90 |
INFECTION |
2 |
0.0000 |
| 91 |
INJECTION SITE SWELLING |
1 |
0.0000 |
| 92 |
INJECTION SITE PAIN |
4 |
0.0000 |
| 93 |
ARTHRITIS |
1 |
0.0000 |
| 94 |
INJECTION SITE HAEMORRHAGE |
1 |
0.0000 |
| 95 |
THROMBOSIS |
1 |
0.0000 |
| 96 |
GASTROOESOPHAGEAL REFLUX DISEASE |
1 |
0.0000 |
| 97 |
INTENTIONAL PRODUCT MISUSE |
1 |
0.0000 |
| 98 |
MUSCULOSKELETAL STIFFNESS |
1 |
0.0000 |
| 99 |
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION |
2 |
0.0000 |
| 100 |
NO ADVERSE EVENT |
2 |
0.0000 |
| 101 |
ADVERSE EVENT |
1 |
0.0000 |
| 102 |
NASOPHARYNGITIS |
2 |
0.0000 |
| 103 |
HYPERSENSITIVITY |
2 |
0.0000 |
| 104 |
COUGH |
3 |
0.0000 |
| 105 |
PRURITUS |
4 |
0.0000 |
| 106 |
ATRIAL FIBRILLATION |
1 |
0.0000 |
| 107 |
ALOPECIA |
2 |
0.0000 |
| 108 |
DYSPEPSIA |
1 |
0.0000 |
| 109 |
HEART RATE INCREASED |
1 |
0.0000 |
| 110 |
SINUSITIS |
1 |
0.0000 |
| 111 |
SEIZURE |
1 |
0.0000 |
| 112 |
CHILLS |
1 |
0.0000 |
| 113 |
DRUG INEFFECTIVE |
11 |
0.0000 |
| 114 |
JOINT SWELLING |
1 |
0.0000 |
| 115 |
PRODUCT USE IN UNAPPROVED INDICATION |
2 |
0.0000 |
| 116 |
VISUAL IMPAIRMENT |
1 |
0.0000 |
| 117 |
INJECTION SITE ERYTHEMA |
1 |
0.0000 |
| 118 |
HYPERHIDROSIS |
1 |
0.0000 |
| 119 |
DRY SKIN |
1 |
0.0000 |
| 120 |
PRODUCT QUALITY ISSUE |
1 |
0.0000 |
| 121 |
WEIGHT DECREASED |
2 |
0.0000 |
| 122 |
RASH |
3 |
0.0000 |
| 123 |
OFF LABEL USE |
6 |
0.0000 |
| 124 |
PAIN IN EXTREMITY |
2 |
0.0000 |
| 125 |
BLOOD PRESSURE INCREASED |
1 |
0.0000 |
| 126 |
HOSPITALISATION |
1 |
0.0000 |
| 127 |
ABDOMINAL DISCOMFORT |
1 |
0.0000 |
| 128 |
URINARY TRACT INFECTION |
1 |
0.0000 |
| 129 |
COVID-19 |
1 |
0.0000 |
| 130 |
MUSCLE SPASMS |
1 |
0.0000 |
| 131 |
GAIT DISTURBANCE |
1 |
0.0000 |
| 132 |
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS |
1 |
0.0000 |
| 133 |
DIARRHOEA |
3 |
0.0000 |
| 134 |
MALAISE |
2 |
0.0000 |
| 135 |
INCORRECT DOSE ADMINISTERED |
1 |
0.0000 |
| 136 |
DYSPNOEA |
2 |
0.0000 |
| 137 |
PRODUCT DOSE OMISSION ISSUE |
1 |
0.0000 |
| 138 |
HEADACHE |
2 |
0.0000 |
| 139 |
FALL |
1 |
0.0000 |
| 140 |
FATIGUE |
2 |
0.0000 |
| 141 |
ARTHRALGIA |
1 |
0.0000 |
| 142 |
DEATH |
2 |
0.0000 |
| 143 |
PAIN |
1 |
0.0000 |
| 144 |
NAUSEA |
1 |
0.0000 |